Business Context and Event Date
Phathom Pharmaceuticals, Inc., a Delaware pharmaceutical company, filed a Form 8-K reporting a material definitive agreement entered into on August 1, 2022. The agreement supports the company’s commercial supply of vonoprazan drug substance, or API.
Material Agreement and Key Terms
- Phathom entered into a Vonoprazan Commercial Supply Agreement with Evonik Operations GmbH.
- Evonik will supply commercial quantities of vonoprazan API, and Phathom will purchase specified quantities at volume-based agreed prices.
- Prices may be adjusted for changes in costs incurred by Evonik.
- Subject to pre-existing API purchase obligations, Phathom agreed to purchase up to a specified percentage of its annual API requirements from Evonik. The percentage may be adjusted based on API pricing.
- The initial term is five years from August 1, 2022. The term extends to seven years if Evonik qualifies a second API manufacturing facility by December 31, 2024.
- Termination, renewal, breach, notice, delivery, payment, confidentiality, intellectual property, warranty, and indemnification provisions are included.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It also does not disclose the contracted API volumes, pricing, minimum purchase commitments, or aggregate financial commitment.
Changes, Outlook, and Risks
The agreement establishes a commercial API supply relationship but does not provide financial guidance or an updated business outlook. Key potential risks include API cost changes, dependence on Evonik for supply, manufacturing facility qualification, purchase-volume obligations, and the possibility of termination or nonrenewal under the agreement.
The complete agreement is expected to be filed as an exhibit to Phathom’s Form 10-Q for the quarter ending September 30, 2022, with certain portions potentially redacted for confidentiality.
Investor Verification Items
- Verify the final filed supply agreement and any redacted provisions.
- Review specified API purchase percentages, minimum commitments, pricing formulas, and cost-adjustment provisions.
- Assess whether Evonik qualifies the second manufacturing facility by December 31, 2024.
- Evaluate Phathom’s reliance on Evonik and the agreement’s termination and renewal conditions.
- Review subsequent filings for financial commitments, supply interruptions, or changes to vonoprazan commercialization plans.